Summary

The United States has a large and growing population, and the prevalence of diabetes is significant. According to the Centers for Disease Control and Prevention (CDC), more than 34 million people in the United States have diabetes, with around 1.5 million new cases diagnosed every year. The high incidence of diabetes drives the demand for blood glucose monitoring devices. The U.S. has a well-developed and advanced healthcare infrastructure. This includes a robust system of healthcare facilities, trained medical professionals, and easy access to medical technologies. The availability of advanced healthcare facilities encourages the adoption of innovative medical devices like blood glucose monitors. There is a high level of healthcare awareness among the population, and people are generally well-informed about the importance of monitoring and managing diabetes. Healthcare professionals often recommend regular blood glucose monitoring for diabetes management, leading to a higher demand for glucose monitoring devices. Insurance coverage and reimbursement policies play a crucial role in the adoption of healthcare technologies. In the U.S., health insurance often covers the costs associated with blood glucose monitoring devices, making them more accessible to a larger portion of the population. According to the national center for health statistics, more than 30 % of adults aged 18 and over in the United States will be obese in 2021. In obese individuals, the fat cells in the body release pro-inflammatory chemicals, which may make the body less sensitives to theinsulin it peoduces by disrupting the function of insulin-responsive cells. Thus, these individuals need external insulin shots and are obligated to use a bllod glucose monitoring device, such as a glucometer. In the United States, there are several innovations in diabetes management platforms by startups like Glooko, OneDrop, Verily, Vascate, Insulet, Noom, Bigfoot Biomedical, Virta Health, Diabeloop and Orgenesis which have lanched in the market. The growing awareness among people regarding advanced diabetes devices is improving the adaptability of blood glucose monitoring devices. Leading manufacture are focusing on technological innovations and developing advanced products to gain a substantial market share.

According to the research report "United States Blood Glucose Monitoring Devices Market Overview, 2028," published by Bonafide Research, the United States Blood Glucose Monitoring Devices market was valued more than USD 6 Billion in 2022. The blood glucose monitor market has seen continuous technological advancements. These include the development of more accurate and user-friendly devices, integration with smartphones and other digital platforms, and the incorporation of artificial intelligence for data analysis. Continuous glucose monitoring (CGM) systems, which provide real-time glucose data, have gained popularity. Blood glucose monitors are increasingly being integrated with digital health platforms and mobile applications. This integration allows users to track and analyze their glucose levels over time, set reminders for medication or testing, and share data with healthcare providers for more personalized care. There is a trend toward designing blood glucose monitors that are user-friendly, with features such as easy-to-read displays, simple navigation, and minimal pain during testing. Accessibility for individuals with different levels of technological proficiency and physical abilities is also a consideration. Beyond traditional glucose monitors, there's a trend toward smart insulin pens and patch pumps that offer additional functionalities. These devices may include dose tracking, reminders, and connectivity with mobile apps for comprehensive diabetes management. Artificial intelligence (AI) and predictive analytics are being increasingly incorporated into blood glucose monitoring systems. These technologies can analyze historical data to predict future glucose trends, providing users and healthcare providers with proactive insights for better decision-making. Wearable technologies, such as smartwatches and fitness trackers, are being leveraged for glucose monitoring. Some devices now offer continuous glucose monitoring features alongside other health and fitness tracking capabilities, contributing to a more holistic approach to health management.

The market is segmented is divided into Self-monitoring Devices and Continuous Blood Glucose Monitoring Devices. The United States has a relatively high prevalence of diabetes, both type 1 and type 2. Given the large population affected by diabetes, there is a substantial demand for blood glucose monitoring devices for regular self-monitoring. The incidence of diabetes in the United States has been on the rise, driven by factors such as sedentary lifestyles, poor dietary habits, and an aging population. This increased incidence contributes to a growing market for blood glucose monitoring devices. Many individuals with diabetes prefer self-monitoring of blood glucose levels as it allows them to actively participate in their own care. Self-monitoring empowers patients to make real-time decisions about their diet, medication, and lifestyle. Insurance coverage and reimbursement policies often support the use of self-monitoring devices. When these devices are covered by insurance, it reduces the financial burden on individuals, making them more likely to invest in and use self-monitoring tools. The cultural acceptance of personal health tracking, encouraged by the popularity of fitness trackers and wellness apps, extends to blood glucose monitoring. Individuals are increasingly comfortable using technology to monitor and track various aspects of their health, including blood glucose levels.

Based on end user the market is segmented into Hospitals, Home Care and Diagnostic Centers. The prevalence of diabetes in the United States has been steadily increasing. With a growing diabetic population, there's a greater demand for diagnostic services to monitor blood glucose levels, contributing to the growth of the Diagnostic Centers segment. Diagnostic centers often use advanced and precise blood glucose monitoring devices to ensure accurate results. The emphasis on diagnostic accuracy and precision in these settings can drive healthcare providers and individuals with diabetes to choose diagnostic centers for regular monitoring. Insurance coverage and reimbursement policies may support blood glucose monitoring services provided by diagnostic centers. Favorable reimbursement practices can encourage individuals to choose diagnostic centers for their monitoring needs. Diagnostic centers often employ point-of-care testing (POCT) for blood glucose monitoring. POCT offers rapid and on-the-spot results, making it convenient for both healthcare providers and patients, thereby contributing to the segment's growth. Diagnostic centers that emphasize continuous monitoring and long-term care for chronic conditions, including diabetes, may attract individuals looking for comprehensive and ongoing support in managing their health.

Recent Developments:
• Dexcom announced on December 20, 2022, that the FDA had approved the Dexcom G7 CGM, its next-generation product. For those with diabetes of any kind who are two years of age or older, the G7 is approved.
• Abbott said that the Freestyle Libre 3 is already stocked at pharmacies across the country following FDA approval in May 2022.

Considered in this report:
• Geography: United states
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:
• United States Blood Glucose Monitoring Devices market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product
• Self-monitoring Devices
• Continuous Blood Glucose Monitoring Devices

By End User
• Hospitals
• Home Care
• Diagnostic Centers

By Indication
• Diabetes
• Pregnancy
• Cardiovascular Disorders & Hypertension
• Cancer
• Respiratory Diseases
• Movement Disorders
• Hearing Disorders
• Wound Care
• Other Indications (sleep disorders, kidney disorders, neurovascular diseases, and HIV)

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Blood Glucose Monitoring Devices industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.

ページTOPに戻る

Table of Contents